Abstract

Clinical Pharmacology & TherapeuticsVolume 91, Issue 3 p. 450-458 Articles Adoption of Pharmacogenomic Testing by US Physicians: Results of a Nationwide Survey E J Stanek, Corresponding Author E J Stanek eric_stanek@medco.com Medco Research Institute, LLC, Medco Health Solutions, Inc., Bethesda, Maryland, USASearch for more papers by this authorC L Sanders, C L Sanders Medco Research Institute, LLC, Medco Health Solutions, Inc., Bethesda, Maryland, USASearch for more papers by this authorK A Johansen Taber, K A Johansen Taber Division of Science, Medicine, and Public Health, American Medical Association, Chicago, Illinois, USASearch for more papers by this authorM Khalid, M Khalid Medco Research Institute, LLC, Medco Health Solutions, Inc., Bethesda, Maryland, USASearch for more papers by this authorA Patel, A Patel Medco Research Institute, LLC, Medco Health Solutions, Inc., Bethesda, Maryland, USASearch for more papers by this authorR R Verbrugge, R R Verbrugge Medco Research Institute, LLC, Medco Health Solutions, Inc., Bethesda, Maryland, USASearch for more papers by this authorB C Agatep, B C Agatep Medco Research Institute, LLC, Medco Health Solutions, Inc., Bethesda, Maryland, USASearch for more papers by this authorR E Aubert, R E Aubert Medco Research Institute, LLC, Medco Health Solutions, Inc., Bethesda, Maryland, USASearch for more papers by this authorR S Epstein, R S Epstein Medco Research Institute, LLC, Medco Health Solutions, Inc., Bethesda, Maryland, USASearch for more papers by this authorF W Frueh, F W Frueh Medco Research Institute, LLC, Medco Health Solutions, Inc., Bethesda, Maryland, USASearch for more papers by this author E J Stanek, Corresponding Author E J Stanek eric_stanek@medco.com Medco Research Institute, LLC, Medco Health Solutions, Inc., Bethesda, Maryland, USASearch for more papers by this authorC L Sanders, C L Sanders Medco Research Institute, LLC, Medco Health Solutions, Inc., Bethesda, Maryland, USASearch for more papers by this authorK A Johansen Taber, K A Johansen Taber Division of Science, Medicine, and Public Health, American Medical Association, Chicago, Illinois, USASearch for more papers by this authorM Khalid, M Khalid Medco Research Institute, LLC, Medco Health Solutions, Inc., Bethesda, Maryland, USASearch for more papers by this authorA Patel, A Patel Medco Research Institute, LLC, Medco Health Solutions, Inc., Bethesda, Maryland, USASearch for more papers by this authorR R Verbrugge, R R Verbrugge Medco Research Institute, LLC, Medco Health Solutions, Inc., Bethesda, Maryland, USASearch for more papers by this authorB C Agatep, B C Agatep Medco Research Institute, LLC, Medco Health Solutions, Inc., Bethesda, Maryland, USASearch for more papers by this authorR E Aubert, R E Aubert Medco Research Institute, LLC, Medco Health Solutions, Inc., Bethesda, Maryland, USASearch for more papers by this authorR S Epstein, R S Epstein Medco Research Institute, LLC, Medco Health Solutions, Inc., Bethesda, Maryland, USASearch for more papers by this authorF W Frueh, F W Frueh Medco Research Institute, LLC, Medco Health Solutions, Inc., Bethesda, Maryland, USASearch for more papers by this author First published: 25 January 2012 https://doi.org/10.1038/clpt.2011.306Citations: 44Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onFacebookTwitterLinked InRedditWechat Abstract To develop a benchmark measure of US physicians' level of knowledge and extent of use of pharmacogenomic testing, we conducted an anonymous, cross-sectional, fax-based, national survey. Of 397,832 physicians receiving the survey questionnaire, 10,303 (3%) completed and returned it; the respondents were representative of the overall US physician population. The factors associated with the decision to test were evaluated using χ2 and multivariate logistic regression. Overall, 97.6% of responding physicians agreed that genetic variations may influence drug response, but only 10.3% felt adequately informed about pharmacogenomic testing. Only 12.9% of physicians had ordered a test in the previous 6 months, and 26.4% anticipated ordering a test in the next 6 months. Early and future adopters of testing were more likely to have received training in pharmacogenomics, but only 29.0% of physicians overall had received any education in the field. Our findings highlight the need for more effective physician education on the clinical value, availability, and interpretation of pharmacogenomic tests. Clinical Pharmacology & Therapeutics (2012); 91 3, 450–458. doi:10.1038/clpt.2011.306 Citing Literature Supporting Information Filename Description cptclpt2011306-sup-0001.docapplication/doc, 137.5 KB Supplementary Table S1 cptclpt2011306-sup-0002.docapplication/doc, 142.5 KB Supplementary Table S2 cptclpt2011306-sup-0003.pdfPDF document, 78 KB Supplementary Data Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article. Volume91, Issue3Regulatory ScienceMarch 2012Pages 450-458 RelatedInformation